High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study

Autor: François Vergez, Alexa S. Green, Jerome Tamburini, Jean-Emmanuel Sarry, Baptiste Gaillard, Pascale Cornillet-Lefebvre, Melanie Pannetier, Aymeric Neyret, Nicolas Chapuis, Norbert Ifrah, François Dreyfus, Stéphane Manenti, Cecile Demur, Eric Delabesse, Catherine Lacombe, Patrick Mayeux, Didier Bouscary, Christian Recher, Valerie Bardet
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Zdroj: Haematologica, Vol 96, Iss 12 (2011)
Druh dokumentu: article
ISSN: 0390-6078
1592-8721
DOI: 10.3324/haematol.2011.047894
Popis: Background Acute myeloid leukemias arise from a rare population of leukemic cells, known as leukemic stem cells, which initiate the disease and contribute to frequent relapses. Although the phenotype of these cells remains unclear in most patients, these cells are enriched within the CD34+CD38low/− compartment expressing the interleukin-3 alpha chain receptor, CD123. The aim of this study was to determine the prognostic value of the percentage of blasts with the CD34+CD38low/−CD123+ phenotype.Design and Methods The percentage of CD34+CD38low/−CD123+ cells in the blast population was determined at diagnosis using flow cytometry. One hundred and eleven patients under 65 years of age with de novo acute myeloid leukemia and treated with intensive chemotherapy were retrospectively included in the study. Correlations with complete response, disease-free survival and overall survival were evaluated with univariate and multivariate analyses.Results A proportion of CD34+CD38low/−CD123+ cells greater than 15% at diagnosis and an unfavorable karyotype were significantly correlated with a lack of complete response. By logistic regression analysis, a percentage of CD34+CD38low/−CD123+ higher than 15% retained significance with an odds ratio of 0.33 (0.1–0.97; P=0.044). A greater than 1% population of CD34+CD38low/−CD123+ cells negatively affected disease-free survival (0.9 versus 4.7 years; P
Databáze: Directory of Open Access Journals
Externí odkaz: